Anjali Ganguli
Corporate Officer/Principal bei SYNDAX PHARMACEUTICALS, INC.
Aktive Positionen von Anjali Ganguli
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2015 | - |
Karriereverlauf von Anjali Ganguli
Ehemalige bekannte Positionen von Anjali Ganguli
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Corporate Officer/Principal | 01.02.2014 | 01.05.2015 |
Ausbildung von Anjali Ganguli
University of Michigan | Doctorate Degree |
The University of Chicago | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
- Börse
- Insiders
- Anjali Ganguli
- Erfahrung